Get the Stockscreener App
110.57
0.17%
0.19
Kymera Therapeutics Inc stock is traded at $110.57, with a volume of 585.22K.
It is up +0.17% in the last 24 hours and up +10.71% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
See More
Previous Close:
$110.38
Open:
$114.145
24h Volume:
585.22K
Relative Volume:
0.75
Market Cap:
$9.10B
Revenue:
$51.48M
Net Income/Loss:
$-315.00M
P/E Ratio:
-30.97
EPS:
-3.5708
Net Cash Flow:
$-244.00M
1W Performance:
-4.49%
1M Performance:
+10.71%
6M Performance:
+58.12%
1Y Performance:
+141.16%
1-Day Range:
$108.31
$114.14
1-Week Range:
$107.40
$119.83
52-Week Range:
$36.65
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
110.57 | 9.10B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-03-25 | Resumed | Guggenheim | Buy |
| Oct-24-25 | Reiterated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-18-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Is Kymera Therapeutics Poised for a Breakthrough With KT-621? - Yahoo! Finance Canada
💪💪💪💪💪💪💪💪💪💪💪 - Moomoo
(KYMR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Law firm probes Kymera Therapeutics' officers f... - Pluang
KYMR Maintained by Mizuho -- Price Target Raised to $140 - GuruFocus
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire
Kymera Therapeutics Price Target Raised to $140.00/Share From $120.00 by Mizuho - Moomoo
Mizuho Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $140 - Moomoo
Kymera Therapeutics (KYMR) AGM 2024 Summary - Quartr
Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 Summary - Quartr
Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Form 144 Kymera Therapeutics For: 13 July By Investing.com - Investing.com Nigeria
RBC Capital Markets has adjusted its investment rating for Kymera Therapeutics Inc., downgrading it from "outperform" to "sector perform." - Bitget
Kymera Therapeutics Shares Fall After RBC Downgrade - Moomoo
RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk - marketscreener.com
Kymera's CEO Sold $6 Million in Stock After a 170% Run - The Globe and Mail
Kymera's CEO Sold $6 Million in Stock After a 170% Run - The Motley Fool
BTIG maintains Kymera Therapeutics (KYMR) buy recommendation - MSN
Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN
Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Insider Monkey
Kymera jumps 17% on early enrollment completion in skin disease study - MSN
Kymera's High-Flying Stock Meets Insider Selling - Kavout | AI
Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Warren Buffett, Ray Dalio, Scion Asset Management, Brevan Howard, Kymera Therapeutics Inc (KYMR), Sony Group Corp (SONY), and More - Insider Monkey
Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics (KYMR) Citi's Biopharma Back to School Conference Summary - Quartr
Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock - Moomoo
Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com - Investing.com Canada
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com - Investing.com India
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock - Investing.com
Form 144 Kymera Therapeutics For: 7 July By Investing.com - Investing.com Nigeria
Kymera Therapeutics, Inc. Announces Appointment of Elizabeth Laws as Senior Vice President - marketscreener.com
Kymera hires ex-Sanofi executive to lead KT-621 development - Investing.com
Kymera hires ex-Sanofi executive to lead KT-621 development By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader - The Manila Times
Kymera Therapeutics Insider Sold Shares Worth $8,864,829, According to a Recent SEC Filing - Moomoo
KYMRKymera Therapeutics Inc Options - Finviz
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade) (NASDAQ:KYMR) - Seeking Alpha
Kymera: Building Toward A Defining 2H26 Moment (NASDAQ:KYMR) - Seeking Alpha
Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift - Yahoo Finance
Kymera Therapeutics(KYMR.US) Officer Sells US$9.22 Million in Common Stock - Moomoo
How Accelerated KT-621 Trial, Index Additions, and New Chair Will Impact Kymera Therapeutics (KYMR) Investors - Yahoo Finance
Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics I - GuruFocus
Kymera Therapeutics director Bruce Booth sells $8.28m in shares By Investing.com - Investing.com Australia
Kymera Therapeutics director Bruce Booth sells $8.28m in shares - Investing.com
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):